Table 1.

Clinical and demographic characteristics of 162 patients treated by self-expanding metal stents for malignant gastrointestinal obstruction

Age [median (range)]	72 (33–93)
Gender M/F	99/63
Survival [median (range)] (days)	111 (15–535)
Diagnoses
Colon cancer	49 (30%)
Pancreatic cancer	41 (25%)
Gastric cancer	18 (11%)
Esophageal cancer	28 (17%)
Bile duct cancer	9 (6%)
Other malignanciesa	17 (11%)
Other palliative treatment
Chemotherapy (during day 0–14)	18 (11%)
Radiotherapy (during day 0–14)	7 (4%)
Stent locations
Esophageal	41 (25%)
Gastroduodenal	33 (20%)
Biliary	40 (25%)
Colon	48 (30%)

^aBreast cancer, n = 1, lymphoma, n = 1; lung cancer, n = 3; prostate cancer, n = 2; hepatocellular carcinoma, n = 1; gallbladder cancer, n = 1; thyroid cancer, n = 1; papillary cancer, n = 1; ovarian cancer, n = 3; duodenal cancer, n = 1; malignant melanoma, n = 2